Litcius/Paper detail

Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors

David Starks, Luis Rojas‐Espaillat, Tobias Meißner, Casey Williams

2022Gynecologic Oncology21 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNeutropeniaPaclitaxelInternal medicineAdverse effectDosingCohortFebrile neutropeniaAnemiaChemotherapyGastroenterologyOncologyPI3K/AKT/mTOR signaling in cancerCancer Treatment and PharmacologyPARP inhibition in cancer therapy
Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors | Litcius